A practical reference on REV-ERB agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Cambridge University Press. ISBN 978-1-009-04573-5. Morano-Faodi, Sonia & Jen Neller. Fairhurst's law of the European Union, 13th edn. Harlow/NY: Pearson Education, 2020. O'Neill, Aidan (2011). EU Law for UK Lawyers (2nd ed.). Bloomsbury Publishing. ISBN 9781847318107. Reich, Norbert, Annette Nordhausen-Scholes, & Jeremy Scholes. Understanding EU internal market law, 3rd rev'd edn. Cambridge: Intersentia, 2015. Riesenhuber, Karl, ed. European legal methodology, 2nd edn. Cambridge: Intersentia, 2021. Schütze, Robert (2025). European Union Law (4th ed.). Oxford: Oxford University Press. ISBN 9780198941057. Tobler, Christa; Beglinger, Jacques (2020). Essential EU Law in Charts. Budapest HVG-ORAC. ISBN 978-963-258-489-8. Weiler, JHH (1991). "The Transformation of Europe". Yale Law Journal. 100 (8): 2403–2483. doi:10.2307/796898. ISSN 0044-0094. JSTOR 796898.
During his stay in Shanghai, Lula criticized US dollar dominance stating "Who was it that decided that the dollar was the currency after the disappearance of the gold standard?" and "why can't we do trade based on our own currencies?". He also urged developing nations to find an alternative currency to the dollar. On 14 April, Lula separately met with Congress chairman Zhao Leji, Chinese premier Li Qiang and Chinese leader Xi Jinping in Beijing and signed numerous agreements (worth BRL 50 billion – nearly US$10.1 billion) aiming at mutual cooperation such as to further develop the CBERS-4 constellation, to create a pannel to follow the Sustainable Development Goals in both countries and to open a Sino-Brazilian trade fair mainly focused on green, low-carbon economy and digitalization, among other agreements. China and Brazil also urged developed countries to speed up climate change mitigation funds following the rich countries' commitment at the COP 15 to donate US$100 billion a year to do so from 2009 on. In July 2024, Brazil and China signed an agreement to extend tourist and business visas validity from 5 to 10-years long. In July 2024, Vice-President Geraldo Alckmin visited China amid the celebrations of bicentenary of the establishment of the Brazilian-Chinese relations, and also reportedly as a preparation for Brazil to join the Chinese Belt and Road Initiative. During the visit Chinese leader Xi Jinping praised Sino-Brazilian relations as a "friendship" that "goes far beyond the bilateral relations".
=== Glaucoma === As a parasympathomimetic miotic, aceclidine decreases intraocular pressure by stimulating muscarinic receptors in the eye, which constricts the pupil and opens the trabecular meshwork to facilitate aqueous humor outflow. It was used as a topical drop in the treatment of narrow-angle and open-angle glaucoma. The clinical utility of aceclidine in glaucoma is comparable to other cholinergic miotics such as pilocarpine, though aceclidine was associated with less ciliary muscle spasm and fewer accommodative disturbances. The use of aceclidine for chronic glaucoma management has declined as other therapeutic classes, such as beta-blockers and prostaglandin analogs, became available.
Sources: en.wikipedia.org
=== VfB Leipzig (1991–2004) === The re-unification in 1990 was followed by the merger of the football leagues of the two Germanies a year later. A poor season led to a seventh-place finish in the transitional league, but an unexpectedly strong playoff propelled the club into the 2. Bundesliga. 1. FC Lokomotive grasped at their former glory by reclaiming the name VfB Leipzig. A third-place finish in 1993 advanced the team to the top-flight Bundesliga, where they finished last in the 1994 season. The new VfB began a steady slide down through the 2. Bundesliga into the Regionalliga Nordost (III) by 1998 and then further still to the NOFV-Oberliga Süd (IV) by 2001. They were bankrupted in 2004, their results were annulled, and the club was dissolved.
This allowed the development of thoracic surgery, which had previously been vexed by the pendelluft problem in which the bad lung being operated on inflated with patient exhalation due to the loss of vacuum with the thorax being open to the atmosphere. Eventually by early 1980s double lumen endotracheal tubes made out of clear plastic enabled anesthesiologists to selectively ventilate one lung while using flexible fiberoptic bronchoscopy to block off the diseased lung and prevent cross contamination. One early device, the copper kettle, was developed by Dr. Lucien E. Morris at the University of Wisconsin. Sodium thiopental, the first intravenous anesthetic, was synthesized in 1934 by Ernest H. Volwiler (1893–1992) and Donalee L. Tabern (1900–1974), working for Abbott Laboratories. It was first used in humans on 8 March 1934 by Ralph M. Waters in an investigation of its properties, which were short-term anesthesia and surprisingly little analgesia. Three months later, John Silas Lundy started a clinical trial of thiopental at the Mayo Clinic at the request of Abbott Laboratories. Volwiler and Tabern were awarded U.S. Patent No. 2,153,729 in 1939 for the discovery of thiopental, and they were inducted into the National Inventors Hall of Fame in 1986. In 1939, the search for a synthetic substitute for atropine culminated serendipitously in the discovery of meperidine, the first opiate with a structure altogether different from that of morphine.
==== Public figure ==== Throughout the fifties and sixties, Adorno became a public figure, not simply through his books and essays but also through his appearances in radio and newspapers. In talks, interviews, and round-table discussions broadcast on Hessen Radio, South-West Radio, and Radio Bremen, Adorno discussed topics as diverse as "The Administered World" (September 1950), "What is the Meaning of 'Working Through the Past?'" (February 1960), and "The Teaching Profession and its Taboos" (August 1965). Additionally, he frequently wrote for Frankfurter Allgemeine, Frankfurter Rundschau, and the weekly Die Zeit. At the invitation of Wolfgang Steinecke, Adorno took part in the Darmstadt Summer Courses for New Music in Kranichstein from 1951 to 1958. Yet conflicts between the so-called Darmstadt school, which included composers like Pierre Boulez, Karlheinz Stockhausen, Luigi Nono, Bruno Maderna, Karel Goeyvaerts, Luciano Berio, and Gottfried Michael Koenig, soon arose, receiving explicit expression in Adorno's 1954 lecture, "The Aging of the New Music," where he argued that atonality's freedom was being restricted to serialism in much the same way as it was once restricted by twelve-tone technique. With his friend Eduard Steuermann, Adorno feared that music was being sacrificed to stubborn rationalization. During this time, Adorno not only produced a significant series of notes on Beethoven (which was never completed and only published posthumously) but also published Mahler: A Musical Physiognomy in 1960.
== Clinical significance == In addition to their roles in cancer development and chemotherapeutic drug resistance, GSTs are implicated in a variety of diseases by virtue of their involvement with GSH. Although the evidence is minimal for the influence of GST polymorphisms of the alpha, mu, pi, and theta classes on susceptibility to various types of cancer, numerous studies have implicated such genotypic variations in asthma, atherosclerosis, allergies, and other inflammatory diseases. Because diabetes is a disease that involves oxidative damage, and GSH metabolism is dysfunctional in diabetic patients, GSTs may represent a potential target for diabetic drug treatment. In addition, insulin administration is known to result in increased GST gene expression through the PI3K/AKT/mTOR pathway and reduced intracellular oxidative stress, while glucagon decreases such gene expression. Omega-class GST (GSTO) genes, in particular, are associated with neurological diseases such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis; again, oxidative stress is believed to be the culprit, with decreased GSTO gene expression resulting in a lowered age of onset for the diseases.
Sources: en.wikipedia.org
Watt phoned the nearby Seaplane Experimental Station at Felixstowe and the superintendent stated that a Supermarine Scapa flying boat had just landed. Watt requested the aircraft return to make more passes. This event is considered the official birth date of radar in the UK. Aircraft from RAF Martlesham Heath took over the job of providing targets for the system, and the range was continually pushed out. During a 24 July test, the receiver detected a target at 40 mi (64 km) and the signal was strong enough that they could determine the target was actually three aircraft in close formation. By September the range was consistently 40 miles, increasing to 80 miles (130 km) by the end of the year, and with the power improvements Bowen worked into the transmitter, was over 100 mi (160 km) by early 1936.
Improved Benevolent and Protective Order of Elks Independent Benevolent and Protective Order of Moose Independent Order of Good Samaritans and Daughters of Samaria - Founded September 14, 1847, as a temperance order in New York City by I. W. B. Smith. It was an authorized branch of the white Grand United Order of Good Samaritans which had been founded that March. Had initiated over 400,000 members by 1897. It was described as having educational as well as mutual benefit aspects including sickness, death, disability, and old age benefits. In 1897 the Order had lodges in every US state and England. Its logo was a dove and olive branch enclosed in a triangle with the words Love, Purity, and Truth emblazoned on them. This symbolized perfection, equality, and the trinity. The Orders headquarters were in Washington, DC. Improved Order of the Shepherds and Daughters of Bethlehem - Founded in 1910 in Richmond, Virginia. Independent Order of Immaculates of the United States of America - Founded June 23, 1872, in Nashville, Tennessee, by W. A. Hadley. Evolved from Young Men's Immaculate Association but was different in that it was patterned after secret fraternal orders and that it admitted men and women. Had about 5,000 members in 1897. Headquartered in Nashville. Independent Order of Saint Luke - Based in Richmond, Virginia. Had 49,498 members at the end of 1921. Attempts to reach it in 1923 were unsuccessful.
Once common on the east coast of Australia, emus are now uncommon there; by contrast, the development of agriculture and the provision of water for stock in the interior of the continent have increased the range of the emu in arid regions. Emus live in various habitats across Australia both inland and near the coast. They are most common in areas of savannah woodland and sclerophyll forest, and least common in heavily populated districts and arid areas with annual precipitation of less than 600 millimetres (24 in). Emus predominantly travel in pairs, and while they can form large flocks, this is an atypical social behaviour that arises from the common need to move towards a new food source. Emus have been shown to travel long distances to reach abundant feeding areas. In Western Australia, emu movements follow a distinct seasonal pattern – north in summer and south in winter. On the east coast their wanderings seem to be more random and do not appear to follow a set pattern.
Motorsport Space travel Sports equipment Sailing Orthopedic technology in orthotics as well as in prosthetics In electrical engineering as an "intermediate layer" in multilayer circuit boards and as insulating material for electrical machines and transformers Rotor blades in wind turbines
organizations as rational systems: Highly formalized structures in terms of bureaucracy's and hierarchy, with formal systems of rules regarding authority and highly specific goals; organizations as natural systems: Participants may regard the organization as an end in itself, not merely a means to some other end. Promoting group values to maintain solidarity is high on the agenda. They do not rely on profit maximization. Their perversity and violence in respect of relationships is often remarkable, but they are characterized by their focus on the connections between their members, their associates and their victims; and, organizations open systems: High levels of interdependence between themselves and the environment in which they operate. There is no one way in which they are organized or how they operate. They are adaptable and change to meet the demands of their changing environments and circumstances. Organized crime groups may be a combination of all three.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.